Heritable skin diseases consist of a group of conditions in which the cutaneous findings can be relatively minor at one end of the spectrum, whereas at the other end the cutaneous manifestations-often part of multisystem pathology-can cause significant morbidity and untimely demise of the affected individuals . Tremendous progress has been made in the past two decades in molecular genetics of heritable skin diseases, and candidate genes and pathogenic mutations have been identified in as many as 500 different genes in a manner that the genetic lesions explain the cutaneous manifestations (Feramisco et al., 2009) . Examination of the mutation databases in different diseases has revealed both obvious candidate genes and a number of surprises, but nevertheless the identification of the mutant genes has been very helpful in providing increased understanding of the pathogenetic mechanisms of these conditions. Many of these diseases could be characterized as metabolic disorders with cellular perturbations, or characterized as multisystem diseases with structural defects. Identification of the mutated genes and specific underlying mutations has been instructive not only in providing information of the molecular basis of the disease but also providing critical understanding of the pathophysiologic role of structural components and specific proteins in normal skin. Particularly instructive have been those diseases affecting the structural components of the skin.
This series of milestones articles deals with genetic disorders with cutaneous manifestations affecting primarily the structural components of the skin. These include identification of defects in the cutaneous basement membrane zone in epidermolysis bullosa (Milestone 1), and the role of collagen and elastic fibers in providing physiologic properties to the dermis, as exemplified by the Ehlers--Danlos syndrome, cutis laxa, and pseudoxanthoma elasticum (Milestones 2-4). Heritable filaggrin disorders, with atopic dermatitis as the paradigm, have provided critical information on the role of epidermal barrier function under physiologic conditions (Milestone 5) , and dissecting the genetics of structural hair disorders has been highly instructive in understanding the growth and maintenance of normal hair (Milestone 6). In a broader sense, development of the next-generation diagnostics (Milestone 7) and molecular therapeutics (Milestone 8) for these disorders is the next step to build improved diagnosis and treatment of these, currently often intractable, disorders.
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INTRODUCTION
Inherited epidermolysis bullosa (EB) represents a clinically and genetically heterogeneous group of genodermatoses characterized by skin fragility, i.e., blisters and erosions of skin and mucous membranes in response to minor friction or mechanical trauma (Figure 1a -e). EB comprises a broad spectrum of phenotypes, ranging from severe cutaneous and extracutaneous involvement caused by severely compromised dermal-epidermal or intra-epidermal adhesion to discrete traits caused by subtle molecular defects. On the basis of our current knowledge, mutations in 17 different genes account for the genetic and allelic heterogeneity of EB (Figure 1 ). The EBassociated genes code for intracellular, transmembrane, or extracellular proteins involved in cytoskeleton, cell-cell or cell-matrix adhesion (Figure 1f ). The main adhesive structures in the skin, i.e., desmosomes, hemidesmosomes, basement membrane, and anchoring fibrils represent supramolecular protein complexes and networks that not only assure the integrity and mechanical stability of the integument, but also regulate cellular functions by transmitting signals between the cells and their extracellular milieu. Therefore, the heterogeneity and the partial overlap between clinical and molecular EB subtypes are not surprising if one considers the high density of molecules and their complex interactions in cell-cell and cell-matrix adhesions.
HISTORICAL PERSPECTIVE
The term EB (implying involvement limited to epidermis) was coined by Koebner more than 120 years ago (Koebner, 1886) . It has remained in use until today, although this group of disorders now encompasses the entire spectrum of known skin fragility disorders, a concept sometimes difficult to comprehend by the patients and some clinicians as well. In the first half of the 20th century, the major achievements in the EB field consisted of defining clinical entities and distinguishing between inherited and acquired forms of bullous diseases. In the 1960s, ultrastructural studies led to the classification of EB into three major typessimplex, junctional, and dystrophicbased on the precise level of tissue separation (Pearson, 1962; Hashimoto et al., 1975; Rodeck et al., 1980; first milestone) . In the 1970s and 1980s, a plethora of clinically distinct EB subtypes were defined, often designated by eponyms. In particular, the monograph published in 1971 by Tobias GeddeDahl included meticulously collected data on more than 100 patients with EB (Gedde-Dahl, 1971 ).
In the 80s, development of immunofluorescence techniques and generation of polyclonal and monoclonal antibodies resulted in the identification of the first molecules causally involved in EB and the establishment of first molecular criteria for diagnosis using immunofluorescence mapping of the dermal-epidermal junction ( (Hintner et al., 1981) , reviewed in (Fine, 1987) ). This was the second milestone in our pathogenetic understanding of this group of disorders.
In parallel, rapid improvements in protein biochemical methods and recombinant protein expression systems facilitated the isolation and molecular characterization of the proteins of the dermal-epidermal basement membrane zone or their functional domains. Using molecular tools, combined with immunoelectron microscopy, such pivotal adhesion proteins as laminin-332 (previously kalinin, laminin 5) and collagen VII were identified as structural components of the hemidesmosomes and the anchoring fibrils (Sakai et al., 1986; Bruckner-Tuderman et al., 1987 , 1988 Marinkovich et al., 1992 Marinkovich et al., , 1993 Urban, 2012) . All the new knowledge and diagnostic advances acquired during this decade were reflected in the revised clinical and laboratory criteria for EB, published in 1991, which split EB into numerous clinical subtypes (Fine et al., 1991) .
The 1990s were marked by rapid progress in genetics, which was based on the development of molecular genetic methods, including gene cloning, linkage analyses for gene mapping, and efficient DNA sequencing. In 1991, KRT14 mutations were found to cause EB simplex, the most common EB type (Coulombe et al., 1991) . Thereafter, in rapid succession, mapping and discovery of the genetic defects underlying several different EB subtypes were reported (Ryynanen et al., 1991a (Ryynanen et al., , 1991b (Ryynanen et al., , 1992 Hovnanian et al., 1992; Christiano et al., 1993; Hilal et al., 1993; McGrath et al., 1995; Li and Uitto, 2012) . Molecular genetic diagnostics became available, but were still labor-intensive, expensive, and dependent on pre-screening. In parallel to the elucidation of new genetic defects and different kinds of mutations in the known genes, researchers started to explore the molecular mechanisms underlying keratinocyte fragility in EB simplex and dermal-epidermal destabilization in junctional and dystrophic EB. In 1997, revertant mosaicism, i.e., genetic reversion of inherited mutations was recognized clinically in patients with junctional EB and demonstrated on molecular genetic level (Jonkman et al., 1997) . For many years, this phenomenon of natural healing was considered rare and described only in isolated cases. Recently, however, it has become clear that revertant mosaicism occurs in most, if not all EB types, and is more widespread than expected (Lai-Cheong et al., 2011; Kiritsi et al., 2012; McLean and Irvine, 2012) .
CLINICAL CLASSIFICATION
In the beginning of the 21st century, a rich body of molecular genetic data on EB was already available. Mutation databases (http://www.interfil.org, https://portal.biobase-international.com/ hgmd/) and patient registries (https:// grenada.lumc.nl/LOVD2, http://www. deb-central.org/molgenis.do, http://www. col7.info) facilitated both the study of genotype-phenotype correlations and the genetic counselling. Together with the knowledge acquired on biochemical and cell biological disease mechanisms, these data served as prerequisite for rational disease classifications. During the first decade of the 21st century, two revisions of the EB classification were needed to reflect the complexity and significant developments in the field (Fine et al., 2000 (Fine et al., , 2008 . Substantial advances in understanding the molecular basis of many old and new EB forms led to the tendency to avoid splitting of the disease into too many sub-entities and to reduce the use of eponyms. However, this is in part counteracted by continuous progress relating to discovery of new genes in rare EB subtypes.
CLINICAL AND GENETIC FEATURES OF EB SUBTYPES
The most extensive changes have concerned EB simplex. Although the vast majority of EB simplex cases is caused by keratin 5/14 mutations (Figure 1b) , several new causative genes have been identified. BPAG1e (dystonin isoform 4) and plectin mutations can cause cytolysis of basal keratinocytes and mild blistering, and may account for at least some of the molecularly unsolved EB simplex cases (Rezniczek et al., 2010; Liu et al., 2012) . Furthermore, the spectrum of EB simplex has extended to include subtypes with cleavage in the suprabasal epidermal layers, e.g., the plakophilin deficiency and the lethal acantholytic EB. These very rare new forms are caused by genetic defects of desmosomal proteins (McGrath et al., 1997; Jonkman et al., 2005; Pigors et al., 2011) . Hence, our vision on EB has extended to include conditions with perturbed cell-cell adhesion, in which the clinical picture is dominated by skin erosions rather than blisters. The molecular basis of EB simplex superficialis has remained unclear (Fine et al., 2008) , as a mutation in the collagen VII gene, associated with dominant dystrophic EB, was identified in the original family (Fine et al., 1989; Martinez-Mir et al., 2002) . In a number of patients with superficial blisters and erosions (Figure 1a ), transglutaminase 5 mutations indicative of acral peeling skin syndrome have been disclosed (Kiritsi et al., 2010; Pigors et al., 2012) . We believe that it is time to classify acral peeling skin syndrome as a skin fragility disorder, rather than a form of ichthyosis as it is now (Oji, 2010) .
The classification of the junctional EB was simplified by distinction of the lethal (Herlitz) subtype from the others, which were collectively designated as junctional EB-other. Junctional EB Herlitz is defined by loss of laminin-332, and it remains one of the most severe forms of EB. Junctional EB-other encompasses diverse phenotypes, in which blistering ranges from lifelong, generalized (Figure 1c) , to late onset, mild, and localized, depending on the residual expression or activity of the mutated protein. The laryngo-onycho-cutaneous syndrome was included as a junctional EB variant, as it has similar clinical features and is associated with mutations in the a3-chain of laminin-332. Very recently, integrin a3 mutations were discovered in three patients with a new complex phenotype, including junctional EB, congenital nephrotic syndrome, and interstitial lung disease (Has et al., 2012) .
All dystrophic EB subtypes are caused by mutations in the gene encoding collagen VII, the main component of the anchoring fibrils. The clinical presentations vary from severe generalized blistering and scarring ( Figure 1d ) to sole nail dystrophy without skin blistering. Although more than 600 COL7A1 gene mutations are known to date, the genotype-phenotype correlations are understood only in part. The heterogeneity of the allelic subtypes is likely to result from the variable expression and function of mutated collagen VII, with the complex interplay of genetic and environmental modifiers.
Because of the variable (mixed) level of skin cleavage, the Kindler syndrome was recognized as a distinct type of EB. It is clinically characterized by skin blistering during childhood and progressive poikiloderma, skin and mucosal scarring, and predisposition to epithelial skin cancer in adulthood (Figure 1e ). Mutations in the FERMT1 gene encoding kindlin-1 underlie this rare autosomal recessive genodermatosis. From a molecular point of view, the Kindler syndrome and the EB with integrin a3 mutations may be classified separately as focal adhesion disorders, because they impair the functions of focal adhesions, adherence, and signalling platforms, which are needed for epidermal cell adhesion and migration.
CLINICAL PERSPECTIVE
By the end of 2011, more than 1250 different mutations in 17 genes responsible for EB were included in the Human Gene Mutation Database Professional release (2011.4; Harel and Christiano, 2012) . In several countries, mutation analysis is now routinely available, every patient having the right to know his/her own mutation. This development expanded the spectrum of disorders encompassed by the term EB and represents the basis for individualized molecular therapeutic approaches (Cho et al., 2012; Uitto, 2012) .
Many preliminary studies regarding translational approaches in EB have been published during the last decade (Mavilio et al., 2006; Fritsch et al., 2008; Wong et al., 2008; Remington et al., 2009; Wagner et al., 2010; Cho et al., 2012) . In the future, the implementation of novel biologically valid therapies must take into account the balance between the gain and risk. No unique solution will be available for all patients, but the success will rather come with personalized therapies adapted to the individual molecular and clinical constellation (Uitto, 2012) .
CONFLICT OF INTEREST
The authors state no conflict of interest. 
ACKNOWLEDGMENTS

INTRODUCTION
The heritable disorders called Ehlers--Danlos syndrome (EDS) are as disparate as they are fascinating. Their discovery and description has been an intimate part of the growth of our understanding of matrix biology. Joint hypermobility, skin extensibility, abnormal scarring, and tissue friability are the hallmark diagnostic features; however, McKusick (1956) recognized that EDS is under-recognized because when the physical signs are not ''classic'' the diagnosis may be elusive. The medical and scientific history of EDS can be seen in three phases: clinical characterization, biochemical and molecular genetic analysis, and the use of high throughput genomic analysis to extend the phenotypes.
CREATING THE CLINICAL SPECTRUM OF EDS
Hippocrates described the features of this disorder in 400 BC; however, the first medical description of some of the characteristics is credited to van Meek'-ren (1682). Tschernogubow's presentation in 1892 seems to have been largely overlooked in Western Europe, probably because it was written in Russian. Weber (1936) is credited with christening the disorder as EDS in 1936 after Ehlers (1901) and Danlos (1908) , two dermatologists who separately described affected patients in 1901 and 1908, respectively. The same year, Georg Sack, a German physician, described a condition that Barabas later identified as the arterial type. McKusick (1956) provided the first synthesis of the clinical literature on the multisystemic and variable nature of EDS in his 1956 hallmark work on heritable connective tissue disorders. Over a decade later, Barabas (1967) proposed at least three distinct subtypes: classical, varicose, and arterial on the basis of his experience with 27 affected individuals. He suggested that the clinical subtypes reflected discrete etiologies, not simply variable expressions of one disorder. A short time later, Peter Beighton published a series of papers from a landmark clinical investigation of 100 individuals with EDS. He recognized and expanded Barabas' work to a classification of five types (Beighton et al., 1969) . The first group included individuals similar to those initially described with skin hyperextensibility and fragility, with abnormal scarring and bruising, and striking joint hypermobility (the gravis form). The second was similar but the skin findings were less dramatic (mitis). A hypermobility form in which the joint findings were striking almost to the exclusion of skin changes was the third type. The Sack-Barabas group (the fourth type) had very severe vascular fragility and was at risk of arterial rupture and bowel rupture. The fifth group was thought to be X-linked and was characterized by joint hypermobility and intramuscular hemorrhage (Table 1) .
THE FIRST PHASE OF BIOCHEMICAL CHARACTERIZATION OF EDS
During the early phase of clinical characterization, clues to the molecular basis of any of the forms of EDS were sparse, with the exception that light and electron microscopy studies identified abnormalities in the structure of collagens in the dermal matrix (Wechsler and Fisher, 1964; Julkunen et al., 1970) . The dam broke in the early 1970s as a result of tissue analysis to assess interactions/cross-links between collagen molecules, animal studies, and use of cultured cells from selected individuals to examine collagen production. Detailed knowledge of the structure of cross-links and the awareness of their importance in tissue integrity provided the background in which the study of sisters with hypermobility, soft extensible skin, scoliosis recalcitrant to surgical intervention, and ocular globe fragility (Krane et al., 1972; Steinmann et al., 1975) led to the identification of lysyl hydroxylase deficiency. In these sisters, hydroxylated complex cross-links were diminished and the virtual absence of hydroxylation of lysyl residues in triple helical collagen molecules resulted from deficiency of lysyl hydroxylase. Once the gene (PLOD1) was isolated, sequence analysis demonstrated inactivating mutations, the most common of which was a 7-exon duplication mediated by Alu-Alu recombination (Heikkinen et al., 1997) . This was one of the very early demonstrations of the role of repetitive elements in the genome as mediators of deletions or duplications. This disorder, a recessively inherited condition, was called EDS type VI and was the first established true disorder of collagen biosynthesis and structure in humans. Specific mutations in COL1A1 (substitutions of cysteine for arginine residues within the triple helical domain of proa1(I) chains) have been recognized to cause a form of EDS reminiscent of classical type with joint hypermobility, skin hyperextensibility, bruising and abnormal scarring, and predisposition to aortic aneurysm.
2
One family with a specific mutation in COL3A1 is said to have only joint hypermobility with none of the other consequences seen in EDS type IV.
3
We have included these previously identified ''types'' of EDS for historical perspective. They are not included in most classifications.
Cattle with a curious and severe form of skin fragility provided the next step in the identification of human collagen disorders, as well as insight into the question of how an essentially insoluble molecule-collagen-could be synthesized and secreted from cells. The bovine disorder, dermatosparaxis, appeared to be inherited in an autosomal recessive manner, and biochemical studies demonstrated that affected animals failed to process an amino-terminal precursor peptide from all three chains of type I collagen (Lenaers et al., 1971) . As a consequence, collagen fibrillogenesis was impaired and skin integrity compromised (Piérard and Lapière, 1976) . The animal study prompted investigation of tissues from a young woman born with bilateral hip dysplasia/dislocation and very marked joint laxity. Her skin contained a2(I) chains of type I collagen with an extension at the aminoterminal end (Lichtenstein et al., 1973; Steinmann et al., 1980) . Although initially interpreted to result from enzymatic deficiency, studies later showed that the woman had a heterozygous splice donor mutation in intron 6 of one COL1A2 allele that led to exon skipping and loss of the sequence that contained both the propeptide cleavage site and the amino-terminal nonhelical cross-link site (Steinmann et al., 1980) . Consistent with this finding, autosomal dominant inheritance was soon recognized and mutations in the COL1A1 gene that led to loss of the sequences of the homologous exon 6 were found in other affected individuals (Byers et al., 1997) . Although the outcomes of mutations in the preceding acceptor site and succeeding donor site differ in detail, both lead to the same phenotype. Fewer individuals have COL1A1 mutations because COL1A1 donor site mutations lead to use of a cryptic donor site or intron inclusion, each of which leads to a frame shift, premature termination codon, mRNA instability, and an osteogenesis imperfecta phenotype. More than 20 years after the basis of dermatosparaxis was explained, a human form of the disorder (then called EDS VIIC) was identified (Nusgens et al., 1992; Smith et al., 1992) and shown to result from biallelic mutations in ADAMTS2, which encodes the procollagen 1 N-proteinase (Colige et al., 1999) . Variation in the clinical picture reflected the presence of missense mutations rather than the early identified nonsense mutations (Colige et al., 2004) .
The early biochemical discovery phase culminated with the demonstration that alteration in the amount of type III procollagen produced was the underlying cause of EDS type IV, the Sack Barabas type (Pope et al., 1975) . At first thought to be recessive because of its rarity, an isolated individual in a family, and apparent decrease in production of type III procollagen by cells from the parents (Pope et al., 1977) , subsequent analyses of the COL3A1 gene has shown that this is a dominant disorder (Tsipouras et al., 1986) . A single example of bi-allelic mutations has been identified out of more than 600 families studied (Plancke et al., 2009) . Some mutations result in failure to secrete type III procollagen from fibroblasts and accumulation of the protein in the rough ER and marked alteration in dermal structure that led to the idea that type III collagen formed a scaffold on which type I fibrillogenesis occurred (Holbrook and Byers, 1981) . A large clinical study proved it difficult to identify clear genotype phenotype correlations (Pepin et al., 2000) . Recent studies, however, make it clear that heterozygosity for a null mutation in COL3A1 endows an individual with an extended natural history compared with the effects of missense and exon skipping mutations (Leistritz et al., 2011) .
EDS type I/II proved to be more difficult than expected to solve at the molecular level. Ultrastructural studies of the skin showed that there were dramatic alterations in the large dermal collagen fibrils, with variation in fibril diameter and aggregate formation (Vogel et al., 1979) . Despite this, linkage studies in families excluded type I collagen genes as candidates (Sokolov et al., 1991; Wordsworth et al., 1991) . It was the finding of an X:9 chromosomal translocation in a woman with EDS type I and skin pigment alteration with identification of a breakpoint in one COL5A1 allele that shed light upon the molecular basis of the disorder (Toriello et al., 1996) . At the same time, linkage studies and sequencing of both COL5A1 and COL5A2 led to the identification of mutations in individuals with EDS type I/II (Burrows et al., 1996; Nicholls et al., 1996; Wenstrup et al., 1996) . Most affected individuals studied had mutations that led to instability of mRNA derived from one COL5A1 allele (Schwarze et al., 2000; Wenstrup et al., 2000; Malfait et al., 2005) . A critical role of type V collagen in fibril nucleation was established in homozygous COL5A1-knockout mice that failed to survive embryogenesis because no large collagen fibrils were assembled (Wenstrup et al., 2004) .
Although often cited to suggest that only about half of affected individuals with EDS type I or EDS type II (the previous gravis and mitis type and future ''classical type'') have mutations in type V collagen genes (Malfait et al., 2005) , a recent study using more consistent clinical diagnosis places this number closer to 90% (Symoens et al., 2012) . Although genetic studies failed to demonstrate that mutations in type I collagen genes could cause EDS type I/ II (Sokolov et al., 1991; Wordsworth et al., 1991) , biochemical analysis of type I collagens synthesized in culture succeeded. Several individuals with substitutions of arginine by cysteine within the triple helical domain of proa1(I) chains of type I collagen, encoded by COL1A1, had a clinical picture of EDS type I/II and also developed aortic aneurysms or dissection (Nuytinck et al., 2000; Malfait et al., 2007) . In addition, homozygosity or compound heterozygosity for COL1A2-null mutations were found in several people who had a clinical presentation with polyvalvular cardiac involvement, moderate joint hypermobility, skin hyperextensibility, and limited bruising (Schwarze et al., 2004; Malfait et al., 2006 (Götte and Kresse, 2005) .
The hope to restore order, similar to that brought by Beighton's studies of the 1960s, led to a gathering of interested clinicians and geneticists at Villefranche in 1997 and the creation of a new set of clinical and biochemical criteria for the diagnosis of EDS (Beighton et al., 1998) . This new classification abolished the previous Roman numerical system and substituted a ''descriptive'' nomenclature, while at the same time banishing some previous types to an ''other'' category. Created before genetic testing for many disorders became widespread, this classification is showing its age and is in sore need of revision. However, any static classification system may be challenged by the expanding molecular characterization of disorders with some features of EDS. The tensions among a purely clinical classification, a purely genetic classification, and a mixed classification may be difficult to resolve and could satisfy neither clinicians nor molecular geneticists in the long run.
The ''post-Villefranche'' era has experienced a proliferation of EDS types distinguished by clinical and genetic grounds but not yet incorporated into a coherent classification. The elegant studies by Burch et al. (1997) The genomic complexity of this region has proven a significant barrier to molecular diagnostics for this gene.
GENETIC AND GENOMIC ANALYSIS IDENTIFIES MORE TYPES OF EDS AND THEIR GENETIC BASES
Astute observation of distinctive clinical features in consanguineous families coupled with genomic searches led to recognition of several forms of EDS that fall outside the Villefranche classification system. These include the spondylocheiro dysplastic form that results from mutations in SLC39A13 (Fukada et al., 2008; Giunta et al., 2008) . The gene encodes an endoplasmic reticulum-located zinc transporter but additional studies suggested that transforming growth factor-b signaling may also be defective, although the relationship to phenotype is not clear. Mutations in CHST14 (Malfait et al., 2010; Miyake et al., 2010) , which encodes dermatan-4-sulfotransferase 1, confirms the importance of this modification as a part of matrix stability. The mutations result in a musculocontractural form of EDS. Very recently a new form of EDS characterized by kyphoscoliosis, myopathy, and hearing impairment was identified that results from biallelic mutations in FKBP14 (Baumann et al., 2012), a member of the prolyl cis-trans isomerase family. Mutations in a family member, FKBP10, result in a form of osteogenesis imperfecta (Alanay et al., 2010), perhaps because of effects on folding of either the proa chains of type I procollagen or of lysyl hydroxylases. This type of mechanism might help explain the clinical overlaps among one form of osteogenesis imperfecta, EDS type VI, Bruck syndrome, and this new form of EDS. The genetic etiology of another rare form of EDS associated with periventricular heterotopia was established by recognition of the similarity of the neurology features with that of periventricular heterotopia due to FLNA mutations (Sheen et al., 2005) . To date, this is the only confirmed X-linked form of EDS. Most reported individuals are female, consistent with an embryonic lethal effect in males.
FINAL CONSIDERATIONS
The genomic era promises to shed additional light on unsolved forms of EDS. For example, a form of EDS characterized by joint hypermobility, easy bruising, and early periodontal loss without significant inflammation was defined as EDS type VIII. This was shown not to result from mutations in COL3A1 even though some features were shared. Linkage to a locus on the short arm of chromosome 12 (12p13) was identified in a large Swedish family but excluded in others, consistent with locus heterogeneity (Rahman et al., 2003) . To date, the molecular etiology of this form remains to be established. Similarly, the genetic etiology in the majority of persons affected with hypermobile EDS (type III) remains to be determined. There are a variety of challenges to dissecting the genetic causes of hypermobile EDS, including but not limited to the clinical variability, seeming sex-related penetrance, and likely genetic heterogeneity. Identifying and understanding the clinical diversity, genetic etiology, and pathophysiologic mechanisms of various forms of EDS will undoubtedly continue to expand the work of the last 50 years toward understanding the biology of the extracellular matrix and the role of the constituent macromolecules in human disease.
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INTRODUCTION
Cutis laxa (CL) is a skin disorder characterized by prematurely redundant, pendulous, inelastic, and wrinkled skin (Berk et al., 2012) , and is associated with variable involvement of other organs. Both acquired and inherited forms of CL exist and the latter show extensive locus heterogeneity and congenital onset. The main histopathologic and ultrastructural anomalies in the skin of patients with CL are paucity, fragmentation, or disorganization of the dermal elastic fibers (Figure 1a) . Studies of inherited forms of CL have uncovered a growing network of genes (Table 1) . On the basis of congenital nature of most inherited forms of CL, these genes are necessary for elastic fiber biogenesis and are distinct from genes involved in the homeostatic maintenance such as those inhibiting ectopic calcification of the elastic fibers (Li and Uitto, 2012) .
ELASTIC FIBER NETWORK
The elastic fibers consist of microfibrils, elastin, and associated proteins, and show tissue-specific organization (Kielty, 2006) . In the skin, they are organized in horizontally undulating deep dermal elastic fibers (Figure 1b , arrowhead), connected to thinner, vertical elaunin fibers, which show a candelabra-like branching pattern toward the dermal-epidermal junction (Figure 1b, arrow) . The elaunin fibers further branch and terminate in oxytalan fibers, which are composed mostly of microfibrils and anchor the network to the dermal side of the basement membrane. The skin phenotype of patients with CL suggests that the elastic fiber system is not required for the anchoring of the epidermis to the dermis (which is disrupted in blistering diseases) (Bruckner-Tuderman and Has, 2012) , but rather appears to couple the growth of the skin to the rest of the body.
MOLECULAR BASIS OF CL
Studies on X-linked CL provided the first insight in to the molecular basis of this disease by showing reduced activity of lysyl oxidase, an enzyme required of the cross-linking of both elastin and collagens (Byers et al., 1980) (Byers and Murray, 2012) . X-linked CL was recognized to be identical to occipital horn syndrome, found to be allelic to Menkes disease, and to be caused by mutations in the copper transporter ATP7A (Kaler et al., 1994) . The activity of lysyl oxidase and several other enzymes (tyrosinase, dopamine b-hydroxylase) is dependent on copper.
Genes encoding known components of the elastic fibers became candidate genes for CL. First, mutations in the elastin gene (ELN) were identified in autosomal dominant CL (ADCL) (Tassabehji et al., 1998; Zhang et al., 1999) , characterized by a relatively mild course, but sometimes associated with aortic aneurysm and pulmonary emphysema (Urban et al., 2005; Szabo et al., 2006) . The ELN mutations responsible for ADCL result in a protein deficient in interacting with microfibrils but with increased self-association (Callewaert et al., 2011) . Incorporation of mutant elastin into the elastic fibers results in reduced compliance of tissues (Hu et al., 2010) , consistent with a dominantnegative mechanism.
Autosomal recessive CL type 1 (ARCL1) is a disease with high infantile and childhood mortality because of severe developmental emphysema or vascular defects. The identification of all three genes responsible for ARCL1 was greatly aided by the similarity in phenotype to knockout mouse models. ARCL1A associated with arterial tortuosity, aneurysms, and bone fragility is caused by mutations in fibulin-4 (FBLN4/EFEMP2) (Hucthagowder et al., 2006) . ARCL1B is distinguished by the presence of supravalvular aortic stenosis, and fibulin-5 (FBLN5) is mutated in affected individuals (Loeys et al., 2002) . Finally, ARCL1C, a disease with severe gastrointestinal and urinary involvement, is a result of mutations in the gene for the latent transforming growth factorbeta-binding protein 4 (LTBP4) (Urban et al., 2009) .
All the three genes for ARCL1 (FBLN4, FBLN5, LTBP4) encode secreted, multi-adhesive proteins required for the hierarchical, cell-directed process of elastic fiber assembly (Czirok et al., 2006 These gene identification studies have highlighted the essential role of the secretory pathway in elastic fiber biogenesis. For example, the secretion of the elastin precursor, tropoelastin, is impaired in cells with ATP6V0A2 mutations leading to accumulation of tropoelastin in Golgi vesicles (Hucthagowder et al., 2009) . Conversely, in cells with RIN2 mutations the production of microfibrils and fibulin-5 appears to be disrupted (BaselVanagaite et al., 2009) . These discoveries support the emerging notion that appropriate intracellular sorting and routing of individual elastic fiber proteins, or groups of proteins are essential for normal extracellular fiber assembly.
Whether preassembly (or microassembly) of these components occurs in particular secretory compartments will be an interesting question to address. Another surprising set of molecules implicated in elastogenesis are mitochondrial enzymes of the proline biosynthesis pathway. Both elastin and collagens are proline-rich proteins, and thus their synthesis may be particularly sensitive to the availability of this amino acid. However, not all disease-causing ALDH18A1 mutations affect the flux through the proline biosynthetic pathway (Bicknell et al., 2008) , suggesting that this enzyme, and by extension possibly PYCR1 as well, may have another function more relevant to the disease mechanism. Discovery of how mitochondrial and secretory proteins orchestrate an intracellular milieu conducive to elastic fiber assembly in the extracellular space will open up exciting novel areas of research and new avenues for interventions to treat disorders of the elastic fiber system.
CONCLUSIONS
The phenotypes and associated molecular defects in CL highlight the integration of molecular networks required for elastic fiber biogenesis with pathways associated with other structural skin disorders. Several forms of CL show joint laxity, a hallmark of Ehlers--Danlos syndrome (Byers and Murray, 2012) , and RIN2 mutations result in a phenotype that appears to be intermediate between CL and Ehlers-Danlos syndrome (Syx et al., 2010) . Sparse hair has been described in several CL syndromes including patients with ELN mutations (Szabo et al., 2006) . Moreover, RIN2 mutations result in alopecia (Basel-Vanagaite et al., 2009) . Thus, the elastic fiber system may be connected to the molecular network disrupted in structural hair disorders (Harel and Christiano, 2012) .
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ECTOPIC MINERALIZATION IN SKIN DISEASES
Skin diseases characterized by aberrant accumulation of mineral deposits comprise a heterogeneous group of disorders, often associated with inflammation (Sprecher, 2010) . Examples of such conditions are systemic autoimmune disorders, for example, dermatomyositis, lupus erythematosus, and systemic sclerosis. Localized inflammatory lesions, such as those in acne and skin cancers, can also develop localized foci of mineralization. The mechanisms of ectopic mineralization in these relatively common conditions are largely unknown. However, clues to the mineralization processes affecting the skin have emerged from studies on rare heritable single gene disorders with profound mineralization of the skin. The paradigm of such mineralization disorders is pseudoxanthoma elasticum (PXE), a multi-system disease with protean manifestations in the skin, the eyes, and the cardiovascular system (Neldner, 1988) . In fact, the significant milestones of progress made in understanding this disorder serve as examples of the power of molecular genetics towards identification of the candidate genes and pathogenic mutations, with translational implications (Uitto et al., 2010 (Uitto et al., , 2011 .
PXE-THE PARADIGM OF ECTOPIC MINERALIZATION DISORDERS
PXE was initially described as a clinical syndrome with characteristic skin findings, ocular involvement, and cardiovascular manifestations (Neldner, 1988). The cutaneous lesions, i.e., small yellowish papules, which tend to coalesce into leathery and inelastic skin, demonstrate accumulation of pleiomorphic elastic structures in mid-dermis, which by diagnostic histopathologic examination reveals progressive mineralization. Although the cutaneous findings primarily present a cosmetic problem and do not interfere with the normal life activities, they signify the risk for development of ocular and vascular complications that can be quite debilitating, with considerable morbidity and occasional premature mortality. The skin findings are associated with ocular involvement, manifesting with angioid streaks and progressive loss of visual acuity, occasionally resulting in blindness. The cardiovascular manifestations include hypertension, intermittent claudication, occasional bleeding from the gastrointestinal vessels, and early myocardial infarcts, reflecting calcification of the arterial blood vessels.
CANDIDATE GENES AND GENE DISCOVERY
As the histopathology of skin in PXE reveals abnormal elastic structures, the genes that participate in the synthesis and assembly of the elastic fibers were initially considered as a candidate gene/protein system for mutations in this disorder. This included the elastin gene on chromosome 7q, as well as a number of elastin-associated microfibrillar proteins, such as fibrillins 1 and 2, fibulins 2, 3, and 4, and lysyl oxidases. However, with cloning of the corresponding genes, linkage analyses systematically excluded these chromosomal regions as the sites of ''the PXE gene' ' (Christiano et al., 1992; Raybould et al., 1994) . The first milestone of molecular genetics on PXE consisted of a collaborative teamwork, organized primarily by PXE International, the premiere patient advocacy organization, which established linkage of the PXE gene to the short-arm of chromosome 16 (Le Saux et al., 1999; Cai et al., 2000) . The critical interval initially consisted of B500 kb of human genome that contained four annotated genes, and examination of the human genome database revealed that none of these genes had an obvious connection to extracellular matrix of connective tissue in general or the elastic fiber network in particular. Another milestone consisted of systematic sequencing of these candidate genes, which resulted in identification of the ABCC6 gene as the one harboring mutations in PXE (Bergen et al., 2000; Le Saux et al., 2000; Ringpfeil et al., 2000; Struk et al., 2000) . This gene encodes a transmembrane efflux transporter protein, ABCC6, a member of the family of multi-drug resistance proteins (MRP6). The gene consists of 31 exons spanning B75 kb of the human genome on chromosomal region 16p13.1.
MUTATION SPECTRUM AND GENETIC HETEROGENEITY
Following the initial identification of ABCC6 as the PXE gene, more than 300 distinct mutations representing over 1,000 mutant alleles have been encountered in patients with PXE from varied ancestral and ethnic backgrounds (Chassaing et al., 2005; Miksch et al., 2005; Pfendner et al., 2007; Li et al., 2009a) . The types of mutations include missense and nonsense mutations, intronic mutations causing missplicing, small deletions or insertions within exons resulting in frameshift of translation, as well as large deletions spanning part or the entire coding region of ABCC6, and sometimes even including flanking genes. Two recurrent mutations of high frequency have been identified, one of them being p.R1141X in exon 24, which accounts for B30% of all pathogenic PXE mutations. In addition, a recurrent deletion of exons 23-29 (del23-29; pA999-S1403del) has been found in at least one ABCC6 allele in 20% of US and 12% of European patients. With the expansion of the ABCC6 mutation database, these genetic lesions can be used for confirmation of the clinical diagnosis, carrier detection, and presymptomatic identification of affected individuals. Furthermore, early identification of the disease has aided in increased surveillance of the clinical complications, allowing prevention, and undoubtedly improving the quality of life of the affected individuals.
Although it is clear that mutations in the ABCC6 gene underlie most cases with classic forms of PXE, defects in additional genes have recently been discovered to result in PXE-like cutaneous findings. A particularly intriguing observation, with potential pathomechanistic implications for PXE, was demonstration that patients with vitamin K-dependent coagulation factor deficiency due to mutations in the GGCX gene, can also have PXE-like cutaneous findings (Vanakker et al., 2007; Li et al., 2009b) . In addition to characteristic cutaneous lesions similar to those seen in PXE, i.e., small yellowish papules, these patients demonstrate excessive folding and sagging of the skin with loss of recoil. These patients were initially described as having combined clinical features of both PXE and cutis laxa. However, the cutaneous lesions in these patients depict characteristic mineralization of dermal elastic structures similar to PXE. More recently, another gene, ENPP1, which underlies generalized arterial calcification of infancy, a severe mineralization disease affecting the cardiovascular system that often leads to early demise of the affected individuals within the first few years of life, has also shown to be associated with PXE-like cutaneous findings (Li et al., 2012; Nitschke et al., 2012) .
The GGCX gene encodes an enzyme responsible for g-glutamyl carboxylation of Gla-proteins, such as vitamin K-dependent coagulation factors and matrix Gla-protein, the latter being a powerful anti-mineralization factor expressed in peripheral connective tissues. Most of these patients show inactivating missense mutations in both alleles of GGCX, clinically manifesting with both PXE-like cutaneous findings and bleeding tendency. In some cases, the GGCX mutations were shown to be heterozygous in combination with a heterozygous ABCC6 mutation, manifesting with cutaneous findings consistent with PXE but without coagulation disorder, suggesting digenic inheritance of PXE in this family (Li et al., 2009c) . These milestones attest to the presence of an intricate mineralization/ anti-mineralization network in the skin and indicate that mutations in different genes involved in ectopic tissue mineralization can result in PXE-like phenotypes.
MODEL SYSTEMS AND PATHOMECHANISMS
An early, somewhat puzzling observation on PXE was that the ABCC6 gene is expressed primarily in the liver and to a lesser extent in the proximal tubules of kidneys, and only at very low level, if at all, in tissues demonstrating ectopic mineralization (Belinsky and Kruh, 1999; Scheffer et al., 2002) . The pathomechanistic details of PXE remain unclear, and in particular, the identity of the molecules transported from liver to the circulation by ABCC6 remains to be disclosed. However, significant progress has been made in understanding the molecular nature of PXE. et al., 1989; Kavukcuoglu et al., 2012 ). This mouse model has served as a platform to study the consequences of Abcc6 mutations utilizing skin grafting and parabiotic pairing model systems (Jiang et al., 2009 (Jiang et al., , 2010a . These experiments have provided evidence that PXE is a metabolic disorder in which absence of ABCC6 transporter activity in the liver results in deficiency of circulating anti-mineralization factors, which in wild-type mice prevent precipitation of calcium/phosphate complexes under normal homeostatic conditions (Figure 1 ). One such circulating factor has been suggested to be vitamin K or its derivatives, such as reduced vitamin K-glutathione conjugate, which is required for activation of the matrix Gla-protein by g-glutamyl carboxylase, a vitamin K-dependent enzyme (Borst et al., 2008) . This hypothesis has been tested in Abcc6 The nature of the substrate transported by ABCC6 in the liver has also been examined by development of an in vitro cell-based transporter system (Ilias et al., 2002) . In this system, insect Sf9 cells are transfected with human ABCC6 expression vector, and the cells are then used to make inside-out vesicles that can be used in transport assays. This assay system has revealed that ABCC6 can transport anionic small molecular weight compounds, but specifically, ABCC6 does not transport vitamin K-glutathione conjugate (Fü lö p et al., 2011).
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TREATMENT PROSPECTS FOR PXE
Two lines of milestone studies have suggested potential treatment modalities for PXE, currently an intractable disorder. One of those studies is predicated on prevention of mineralization that could be helpful in lessening the clinical manifestation of PXE irrespective of the pathomechanisms. Specifically, a set of experiments has suggested that supplementation of diet with magnesium will prevent the deposition of mineral in connective tissue (LaRusso et al., 2009; Gorgels et al., 2010; Li and Uitto, 2010) . Specifically, experiments using the Abcc6 À/À animal model have shown that supplementation of the diet with magnesium up to 5-fold completely prevents the development of ectopic mineralization up to 6 months of age. Conversely, diet that is low in magnesium and high in phosphate has been shown to accelerate the mineralization process in PXE mice (LaRusso et al., 2008; Li and Uitto, 2010; Jiang and Uitto, 2012) . Thus, these studies examining the precise role of different mineral components in the diet, using the preclinical animal models, have led to development of clinical trials to test the feasibility of this approach to treat patients with PXE.
Another potential way of preventing ectopic mineralization revolves around the supplementation of anti-mineralization factors to the circulation. One of such molecules is fetuin-A, a powerful anti-mineralization factor that is able to prevent aberrant mineralization under normal physiologic calcium and phosphate homeostatic conditions (JahnenDechent et al., 1997). The possibility of using fetuin-A is strengthened by demonstration that concentrations of fetuin-A in serum of patients with PXE as well as in Abcc6 À/À mice are reduced (Hendig et al., 2006; Jiang et al., 2007) , and in fact, overexpression of fetuin-A in the liver of Abcc6 À/À mice has been shown to result in lessening of the mineralization (Jiang et al., 2010b). Additional strategies aim at regeneration of liver by introduction of allogeneic stem cells with capability to differentiate into hepatocytes, which could result in restoration of functional ABCC6 transporter activity. An extension of this strategy would be liver transplantation or a partial lobe replacement as a means to restore the ABCC6 activity.
An intriguing possibility is that distinct mutations in the ABCC6 gene have different pathomechanistic Figure 1 . Conceptual illustration of the proposed metabolic hypothesis of PXE. Under physiologic conditions, the ABCC6 protein is expressed in high levels in the liver, presumably transporting critical metabolites to the circulation (right panel). In the absence of ABCC6 transporter activity in the liver, changes in the concentration of such substrate molecules in the circulation can take place, and the changes result in mineralization of a number of tissues, such as the eye, the arterial blood vessels, the kidney, and the skin (middle panel). Mutations in the filaggrin gene (FLG) are one of the most common pathogenic single-gene defects identified to date. FLG encodes an important epidermal protein abundantly expressed in the outer layers of the epidermis . Approximately 10% of individuals of European ancestry are heterozygous carriers of a loss-of-function mutation in FLG resulting in a 50% reduction in expressed protein (Irvine and McLean, 2006) .
As a protein, filaggrin is an unusual beast in biology. It is expressed as a giant, inactive, polymeric protein, profilaggrin, which is a major constituent of keratohyalin granules. At the interface between the outermost granular layer keratinocytes and the stratum corneum, this proprotein is cleaved into several identical filaggrin subunits. It has been postulated that these monomers condense the cytoskeleton and contribute to squame formation. In the cornified layers per se, filaggrin undergoes further posttranslational modifications and is ultimately proteolyzed into a hygroscopic pool of amino acids and chemical derivatives thereof, termed natural moisturizing factor (NMF). Thus, filaggrin has a central role in the biogenesis and subsequent hydration of the stratum corneum (Irvine et al., 2011) .
DISEASE ASSOCIATIONS
The identification of an association of filaggrin with atopic dermatitis (AD) was a slow burning one. Shortly after the identification of this protein in the late 1970s (Dale, 1977) , its role in keratin filament aggregation was rapidly established (Dale et al., 1978) . Some 7 years later, the first evidence that filaggrin was of potential causal interest in ichthyosis vulgaris (IV) emerged (Sybert et al., 1985) . It was to take a further two decades to fully disclose the molecular genetics of IV. That delay was due, in large part, to the technical difficulty of sequencing this highly repetitive gene and also due to the confusing inheritance of IV, which it transpired, which was best explained by semi-dominant Mendelian inheritance, rather than by traditionally understood dominant or recessive inheritance (Smith et al., 2006) .
Once Smith et al. (2006) had cracked the technical aspects of sequencing FLG in carefully chosen clinical pedigrees, the first two recurrent loss-of-function mutations (R501X and 2282del4) were identified. Identification of further recurrent mutations swiftly followed (Sandilands et al., 2007) . Surprisingly, these mutations proved to be prevalent in European populations, with B9% of these populations carrying at least one FLG mutation (Irvine et al., 2011 ). An ethnospecific mutation profile was seen with population-specific mutation spectra reported in well-studied populations such as the Singapore Chinese (Chen et al., 2011) . In this population, multiple very low-frequency mutations collectively contribute to the overall total, compared with the Irish population where five recurrent mutations constitute most of the total mutations (Chen et al., 2011) .
Once the molecular genetics had been established, rapid genotyping of large patient collections was possible and the association with AD was established initially in small collections of Irish children with AD and in Scottish children with AD and asthma (Palmer et al., 2006) . These findings have since been replicated many times in varying disease collections and population cohorts; the association is one of the strongest between any gene and a complex disease (Rodriguez et al., 2009) . Further analysis of additional disease and population collections revealed that AD associated with FLG mutations is, in general, more severe, more persistent, more 'atopic', more likely to be associated with asthma, and more likely to have herpes infections (Irvine et al., 2011) . Overall, collections of AD show a prevalence of FLG mutations of between 20 and 50% (Irvine, 2007) . In addition, FLG mutations are associated with peanut allergy (Brown et al., 2011) . The totality of the contribution of filaggrin to human disease is not limited to low prevalence loss-of-function mutations, as more prevalent intragenic copy number mutations also contribute substantially to risk, with the total filaggrin repeat number (the filaggrin index) significantly predicting AD risk with a lower odds ratio but a higher frequency and therefore a significant overall contribution to disease in addition to the lower frequency null alleles (Brown et al., 2012) .
THE ROLE OF FILAGGRIN IN EPIDERMAL BARRIER FUNCTION
The filaggrin story placed a primary epidermal barrier defect firmly in the forefront of AD pathogenesis and has led to multiple avenues of inquiry to elucidate early pathogenic pathways in AD. The flaky tail mouse, a double mutant for murine Flg and the matted gene (ma), shows a primary epidermal barrier defect compounded massively by allergic inflammation (Fallon et al., 2009) findings consistent with ex vivo studies that show evidence for modulation of filaggrin expression by the Th2 cytokines, IL-13 and IL-4 (Howell et al., 2007) . Furthermore, filaggrin may have pleiotropic effects on multiple pathways relevant to the pathogenesis of AD including on the growth of Staphylocccus aureus (Miajlovic et al., 2010) , skin pH (Jungersted et al., 2010) , lipid lamellae secretion and stratum corneum structure (Gruber et al., 2011) , and the expression of pro-inflammatory cytokines (Kezic et al., 2012) . FLG-null alleles lead directly to decreased stratum corneum NMF (Kezic et al., 2008) ; careful assessment of these levels demonstrates three separate subpopulations of AD based on FLG genotype,
, and FLG et al., 2010) .
THERAPEUTIC TARGETS
Filaggrin expression is downregulated in all cases of moderate-to-severe AD (Kezic et al., 2011) , making it an appropriate therapeutic target for AD in the broadest sense, rather than being confined to AD associated with FLG-null alleles. The filaggrin index effect, where a modest 20% increase in filaggrin copy number leads to a 40% reduction in AD susceptibility (Brown et al., 2012) , is highly suggestive that filaggrin upregulation therapies will be of potential wide utility in AD. Comparatively little is known about the regulation of filaggrin gene expression, although this is now an area of active interest by academia and pharma alike. The fact that filaggrin expression has been shown to be regulated by environmental humidity (Katagiri et al., 2003) indicates that there are signaling pathways in the skin that actively control filaggrin expression and skin barrier homeostasis in general. These are tractable problems that will lead to specific therapeutic approaches once these pathways are fully understood and targeted pharmacologically.
INTRODUCTION
The first successful application of positional cloning to a disorder of the skin involved the identification of steroid sulfatase as the gene mutated in X-linked ichthyosis (Ballabio et al., 1987; Yen et al., 1987) . This groundbreaking discovery led to the cataloging of more than 500 unique protein-coding genes, underlying 560 different skin and hair abnormalities (Feramisco et al., 2009; Betz et al., 2012) . Among skin appendages, the hair follicle (HF) has a remarkably complex architecture, comprised of concentric layers of epithelial cells, which surround and support the highly keratinized, rigid hair shaft. The shaft itself consists of a multicellular cortex and the hair cuticle encased by the three layers of inner root sheath (IRS). The IRS is surrounded by the companion layer and the outer root sheath, which is continuous with the basal layer of the epidermis. With every successive hair cycle, the proliferating matrix cells in the anagen hair bulb differentiate and keratinize, giving rise to the layers of the IRS, as well as the cuticle, cortex, and medulla of the hair (Langbein and Schweizer, 2005) . Keratins, desmosomes, and lipids are abundantly expressed in the HF and are essential for maintenance of structural integrity and regulation of apoptosis, stress response, and protein synthesis (Takahashi et al., 2003; Gu and Coulombe, 2007; Kim and Coulombe, 2007) . In this review, we will focus on hereditary hair disorders and discuss the studies that linked these disorders to genes encoding structural components of the HF.
KERATINS AND ASSOCIATED HAIR DISEASES
Keratins are the major structural component of the HF and are generally divided into type I (acidic) and type II (neutral-basic) proteins. In addition to this classification, relating to chromosomal location, gene structure and ability to form heterodimers with the other type, keratins fall into two categories: keratins of the epidermis and the ''hard'' keratins of the hair. Hair keratins possess a highly cysteinerich head and tail domains, allowing them to form tight cross links with keratin-associated proteins. This enables the formation of the tough structure of the hair and nails. Of the 54 functional keratin genes identified by the Human Genome Project, 11 type I keratins, designated as K31-K40, and 6 type II keratins, designated as K81-K86, are expressed specifically in HF and nails (Langbein et al., 1999; Schweizer et al., 2006) . Keratin mutations cause fragility in epithelial cells and mutations in several hair keratins have been linked to human diseases (McLean and Moore, 2011) . The first and most common among the hair keratin diseases is monilethrix, a nonsyndromic hair disorder characterized by fragile, brittle scalp hair, and nail deformities. Morphologically, affected individuals display periodic changes in hair shaft diameter, resulting in a characteristic abnormality called beaded hair. The autosomal dominant form of the disease is caused by missense mutations in the conserved helix termination motifs of the type II hair keratins KRT81, KRT83, and KRT86. These proteins are highly expressed in the hair cortex, and the identification of these mutations provided the first direct evidence for the involvement of hair keratins in hair disease (Winter et al., 1997; van Steensel et al., 2005) . K85 is a type II hair keratin linked to autosomal recessive pure hair and nail ectodermal dyplasia, a disorder manifested as a complete alopecia and nail dystrophy. The K85 protein is abundantly expressed in the matrix, precortex, and cuticle of the hair shaft and appears critical for the proper formation of keratin and desmosomes complexes in the hair and nails. The severity of this phenotype suggests that K85 is more essential to HF structure than proteins involved in monilethrix (Naeem et al., 2006; Shimomura et al., 2010b) . In addition to mutations in hair keratin genes, autosomal recessive mutations in a regulator of hair keratin gene expression, the FOXN1/WHN gene, result in alopecia and nail dystrophy (Frank et al., 1999) . This syndrome, which also includes T-cell immunodeficiency, represents the human counterpart to the nude mouse phenotype (Nehls et al., 1994) .
Of the epidermal keratins, type I keratins, K25-28, and type II keratins, K71-74, are abundantly and differentially expressed in the three layers of the IRS (Langbein et al., 2006; Schweizer et al., 2006) . Mutations in K71, identified in mice and dogs, are linked to the wavy coat phenotype called Caracul (Kikkawa et al., 2003) . Mutations in K74, which is highly expressed in Huxley's layer of the IRS, are associated with autosomal dominant woolly hair (ADWH), a condition characterized by slow hair growth and tightly curled hair (Shimomura et al., 2010c) .
In addition, a recent study identified a missense mutation in K71 as the cause for ADWH in a Japanese family (Fujjmoto et al., 2012) . Taken together, these findings suggest a role for keratins in hair disorders and determinants of normal hair texture variation across species (Shimomura and Christiano, 2010) .
DESMOSOMES AND ASSOCIATED HAIR DISEASE
Desmosomes are cell-cell adhesion complexes essential for morphogenesis, differentiation, and maintenance of tissues subjected to high mechanical stress, such as the skin and the heart. In both follicular and interfollicular epidermis, desmosomes anchor keratin intermediate filaments to the cell membranes and bind adjacent keratinocytes to each other, providing structural integrity and distribution of physical impact throughout tissue (McGrath, 2005; Bazzi and Christiano, 2007) . The major structural components of desmosomes are the desmosomal cadherin family composed of desmogleins (DSGs) and desmocollins (DSCs), and the cytoplasmic plaque proteins plakoglobin (PKG), plakophilins and desmoplakin (DSP) (McGrath, 2005) .
The importance of desmosome proteins to HF development and maintenance was first demonstrated by animal studies. Mutations in Dsg3 were shown to be responsible for the naturally occurring balding mouse, and targeted ablation of this gene resulted in hair loss due to a defect in cell adhesion within the keratinocytes surrounding the club hair (Koch et al., 1998) . Dsg2-knockout mice die around the time of implantation, revealing the importance of this gene in general embryonic development (Eshkind et al., 2002) . More recently, a fourth member of the DSG family, DSG4, was shown to be the predominant DSG expressed in the HF (Bazzi et al., 2006) . DSG4 is a key mediator of keratinocyte cell adhesion in the HF, where it is expressed in the transition zone between proliferation and differentiation (Kljuic et al., 2003) . Mutations in DSG4 cause localized autosomal recessive hypotrichosis (LAH). LAH patients present with hypotrichosis limited to the scalp, chest, arms, and legs (Kljuic et al., 2003) . Some patients with DSG4 mutations display fragile hair shafts with beaded morphology, suggesting that DSG4 is the causative gene for the autosomal recessive form of monilethrix (Schaffer et al., 2006; Shimomura et al., 2006) . Recently, a homozygous, nonsense mutation in DSC3 was reported to cause hypotrichosis and recurrent skin vesicles, a disorder that manifests as sparse scalp hair with fragile hair shafts and persistent fluidfilled skin vesicles (Ayub et al., 2009) . Corneodesmosin (CDSN), together with DSG1 and DSC1, form the modified desmosomes of the epidermis (corneodesmosomes). CDSN is expressed in the IRS, beginning at a later stage of keratinization and continuing until the IRS is degraded (Mils et al., 1992) , suggesting that CDSN has a role in terminal differentiation of the IRS. Indeed, heterozygous nonsense mutations in the CDSN gene cause hereditary hypotrichosis simplex restricted to the scalp. Histological examination of patients' HF showed disruption of the IRS and aggregates of abnormal CDSN around the HF and the papillary dermis, implying that the mutant CDSN protein is acting in a dominantnegative manner (Levy-Nissenbaum et al., 2003) . Naxos and Carvajal syndromes are autosomal recessive disorders causing woolly hair (WH), palmoplantar keratoderma, and cardiomyopathy. These cardiocutaneous syndromes result from protein truncating mutations in the desmosomal components PKG and DSP, respectively (McKoy et al., 2000; Norgett et al., 2000; Bolling and Jonkman, 2009) . Homozygous mutations in the PKG gene (both nonsense and splice site mutations) were also found to underlie skin fragility accompanied by WH, without heart abnormalities. Interestingly, one of these mutations resulted in very sparse WH, whereas patients harbouring the other mutation had abundant WH (Cabral et al., 2010) . Over 40 human mutations in the DSP gene have been shown to cause either skin or heart disease or a combination of skin, hair, and heart abnormalities, demonstrating the importance of this gene for the development and integrity of these tissues. DSP mutations can be associated with WH and hair loss (Bolling and Jonkman, 2009) .
LIPIDS AND ASSOCIATED HAIR DISEASES
Lipids are abundant both in the IRS of the HF and on the surface of the hair shaft cuticle, where they are covalently bound to hair proteins. Integral hair lipids form cell membranes that provide structural support and protect the hair shaft from environmental insults. Recent studies have demonstrated that lysophosphatidic acid (LPA), an active lipid with many biological functions, has a significant role in HF morphogenesis and cycling (Takahashi et al., 2003) . The first report linking lipid biology to hair disorders showed that mutations in lipase H (LIPH) cause autosomal recessive hypotrichosis (Kazantseva et al., 2006) . Subsequent reports have described other mutations in LIPH causing not only hypotrichosis, but also autosomal recessive WH (ARWH) (Ali et al., 2007; Nahum et al., 2009; Shimomura et al., 2009) . These patients feature slow or arrested hair growth, resulting in shorter length of the hair shaft. LIPH encodes a phospholipase responsible for the formation of LPA from phosphatidic acid. LPA signals by binding to the orphan G-protein-coupled receptor P2RY5, encoded by the LPAR6 gene (Yanagida et al., 2009) . Both LIPH and LPAR6 are abundantly expressed in the IRS of the H and are likely involved in maintenance of hair shaft integrity. Accordingly, mutations in LPAR6 were also found to be associated with recessive hypotrichosis and WH. Affected individuals with LIPH or LPAR6 mutations displayed WH primarily during early childhood but then exhibit wide variability in hypotrichosis phenotype with aging (Petukhova et al., 2008; Shimomura et al., 2008) . The range of phenotypes displayed by these patients suggests that they may be influence by other genetic or environmental factors, but taken together, these studies point at a role for LPA-mediated signaling in hair structure and growth.
HAIRLESS AND APCDD1
Although not strictly resulting in structural defects, mutations in two genes, hairless and APCDD1, underlie several important hair disorders. Atrichia with papular lesions (APL) is an autosomal recessive disorder characterized by early onset and complete hair loss, followed by the appearance of dermal cysts over the skin surface (Ahmad et al., 1998; Panteleyev et al., 1999) . Marie Unna hypotrichosis (MUH) is an autosomal dominant disease, presented as sparse scalp hair at birth, followed by complete alopecia or hypotrichosis in adulthood (Lefevre et al., 2000; Sreekumar et al., 2000) . Both syndromes are caused by mutations in the hairless (HR) gene. HR is a zinc finger transcription factor, postulated to function as a histone demethylase (Shimomura and Christiano, 2010) . HR regulates the transition into catagen phase, including processes such as hair club formation, maintenance of dermal papilla-epithelial integrity, and IRS degradation. APL in humans, as well as in several animal models, is caused by homozygous loss-of-function mutations in HR. Strikingly, HR mutations result in abnormal degeneration of epithelial cells in the catagen HF, leaving behind the dermal papilla in the dermis (Ahmad et al., 1998; Panteleyev et al., 1999) . MUH-causing mutations were mapped to the 5 0 UTR of the HR and the results are consistent with a gain of function and regulation at the translational level (Wen et al., 2009) .
Hereditary hypotrichosis simplex, an autosomal dominant disorder, is characterized by degenerative HF miniaturization, leading to the conversion of thick terminal hair to fine vellus hair (Toribio and Quinones, 1974) . APCDD1, a gene abundantly expressed in both epidermal and dermal compartments of the human HF, is mutated in this disease (Shimomura et al., 2010a) . APCDD1 has been implicated in linkage intervals in families with androgenic alopecia (Hillmer et al., 2008) and alopecia areata (Martinez-Mir et al., 2007) . Our laboratory demonstrated that APCDD1 is an inhibitor of the Wnt signaling pathway, raising the possibility that APCDD1 may regulate Wnt-dependent processes in other cell types as well (Shimomura et al., 2010a) .
POSITION EFFECTS AND HYPERTRICHOSIS
A ''position effect'' is defined as an alteration in gene expression caused by a change in the position of a gene relative to its native chromosomal surroundings (Kleinjan and van Heyningen, 1998) . Mechanisms may include chromosomal rearrangements, insertions, deletions, inversions, copy number variation (CNV) among others, thus these diseases tend to be very rare in the population. Paradoxically, a position effect may generate a distinct phenotype from the one(s) caused by loss-of-function mutations in the coding region of the same gene. For example, mutations in TRPS1, a zinc finger transcription factor with GATA and Ikaros-like domains, account for both hypo-and hypertrichosis disorders. Patients with Ambras syndrome display excessive ectopic hair growth and abnormal craniofacial features. Chromosomal rearrangements in these patients mapped to an interval on chromosome 8q, which includes TRPS1 (Tadin et al., 2001; Wuyts et al., 2002; Fantauzzo et al., 2008) . Koala mice carry an inversion just upstream of the Trps1 gene and display excess hair on the muzzle and ears (Fantauzzo et al., 2008) . In contrast, germline mutations in TRPS1 result in autosomal dominant inheritance of trichorhinophalangeal syndromes types I and III. These syndromes are characterized by sparse scalp hair, and craniofacial and skeletal abnormalities (Momeni et al., 2000; Lü decke et al., 2001) . Deletion of the GATA-type zinc finger domain of Trps1 in mice mirrors the phenotype of human TRPS patients (Malik et al., 2002) . Analysis of these mutant mice revealed a role for Trps1 as a repressor of the expression of extracellular matrix proteins (Fantauzzo and Christiano, 2012) . In addition to Ambras syndrome, two additional forms of hypertrichosis have been reported that result from position effects. Autosomal dominant hypertrichosis was linked to a microdeletion on 17q24, near the SOX9 gene (Sun et al., 2009 ), suggesting that CNVs close to this gene, which encodes an essential regulator of HF stem cells (Nowak et al., 2008) , may exert a position effect on the expression of SOX9 (Sun et al., 2009) . Generalized, X-linked hypertrichosis was mapped to chromosome Xq24-q27.1, however, no causative genes have been identified (Figuera et al., 1995) . A recent study revealed an interchromosomal insertion at Xq27.1 in a Chinese family with X-linked congenital hypertrichosis, and suggested that a position effect on SOX3, located upstream of the insertion site, may be responsible for the phenotype (Zhu et al., 2011) , however, the specific genetic mechanism defect for X-linked hypertrichosis remains unknown.
SUMMARY
The identification of causative genes carries the promise of new and innovative therapeutic strategies for both inherited and acquired hair disorders. Moreover, the delineation of the relationships between similar phenotypes, resulting from mutations affecting seemingly distinct regulatory pathways, paves the way to improved diagnosis and treatment. Finally, understanding the biological processes governing HF development and maintenance may have implications for more general disease processes in the skin, such as inflammation and cancer. These data, combined with the development of PCR-based methods for amplification of genomic DNA and mutation detection, led to more accurate diagnoses, better genetic counseling, and translational benefits for patients such as new prenatal diagnostic tests, as well as a platform to develop new disease mechanismbased models and therapies (see Uitto, 2012) . The most prevalent genetic variants causative for specific common disorders (e.g., p.Phe508del in the CFTR gene in cystic fibrosis, and p.Gly6Val in the HBB gene in sickle cell anemia) were deemed clinically and economically suitable to format into focused diagnostic products. In contrast, for the genodermatoses, the relative rarity of these skin diseases and the lack of recurrent mutations meant that molecular progress has not led to similar developments. Notably, DNA diagnostics for inherited skin diseases have remained mostly confined to a few academic and hospital laboratories. Recently, however, gene hunting and mutation detection has moved into an era in which next-generation sequencing technologies recast not only the scientific discovery process but also the logic of detecting such inherited markers in the clinic.
EPIDERMOLYSIS BULLOSA AND THE DIAGNOSTIC JOURNEY
This journey of molecular discovery in inherited skin diseases is exemplified by the disease epidermolysis bullosa (EB) (see Bruckner-Tuderman and Has, 2012) . Transmission electron microscopy in the 1960s was able to establish three distinct levels of blister formation, thus providing diagnostic categories of EB into simplex, junctional, and dystrophic (Pearson, 1962) . In the 1980s, the introduction of antigen mapping (Hintner et al., 1981) and immunofluorescence microscopy using new anti-basement membrane zone antibodies (Fine et al., 1984) was able to speed up diagnostic subtyping-most recessive types of EB could be rapidly diagnosed within 2-3 days based on the skin biopsy immunoreactivity (or lack thereof) to specific probes. In the 1990s, the genes for the major forms of EB were cloned and a plethora of pathogenic mutations emerged (for review, see Varki et al., 2006 Varki et al., , 2007 (Pettersson et al., 2009) . Next-generation sequencing methodologies have reduced the cost of characterization of the 6 billion nucleotides composing a diploid genome to less than $2,000 (April 2012 costs). Affordability of high-resolution epigenetic assessment has kept pace, with interrogation of B80% of genomic CpGs for less than $2,000 and whole-genome localization of histone marks for as little as B$500 (Cheng and Cho, 2012) . The plummeting cost of diagnostics, however, poses paradoxical difficulties-whereas clinicians once grappled with potential diagnoses missed by limited tests, the future is likely to overwhelm with large numbers of genetic variants of uncertain significance.
of a clinical test is a crucial prism to examine the evolution of genetic testing. The simple, consistent conformational changes induced by sickle cell anemia variants have enabled cheap chromatography-based tests, often less than $50 in cost, to persist as firstline screening to the current day (Nalbandian et al., 1975) . Similarly, testing for hexosaminidase A levels adopted broadly in the 1960s remains the most common means of testing for Tay-Sachs disease. However, the cost of DNA sequencing in that interval has dropped to B$150-200 for specific genetic variants. Today, a similar sort of sum (perhaps B$500) can purchase sequencing of the entire protein-coding region of a genome (about 60-70 million nucleotides). Consequently, the greatest competition for the traditional Tay-Sachs test may not be a Tay-Sachs test, but one screening dozens to hundreds of metabolic genes carrying mutations in Ashkenazi Jews (Srinivasan et al., 2010) . The burden of interpreting some of these extremely rare variants, with unpredictable clinical penetrance, falls increasingly on the treating subspecialist.
CREATING A DIAGNOSTIC PATH FOR GENODERMATOSES
With regard to genodermatoses, however, there are some specific challenges. In contrast to classic quantitative traits, such as metabolic disease or blood pressure, the more specific and discrete morphological phenotypes typifying many dermatoses (e.g., epidermal blistering diseases) have revealed surprisingly diverse genes converging on a common phenotype. Today, we understand that a truly comprehensive genetic diagnostic for an unclassified ichthyosis must survey dozens of genes regulating cholesterol metabolism, immunoglobulin regulation, cytoarchitectural components, and determinants of terminal keratinocyte differentiation, each candidate defect linked to a distinct spectrum of systemic manifestations (Oji et al., 2010) . The morpho-spatial nature of genodermatoses also adds the conundrum of mosaic disease (Cho, 2010) .
The visible lesions defining the skin disease may represent clonal mutations (as in epidermal nevi), and any genetic testing must therefore sample affected tissue directly in these disorders. In the absence of available commercial therapeutics for many of these conditions, let alone genetic counselors familiar with the clinical implications of rare genodermatoses, the impetus to advance such testing has often come from patients rather than clinicians or pharmaceutical companies.
EXOME SEQUENCING AND THE WAY AHEAD
Exome sequencing represents a significant milestone in the development of next-generation diagnostics for inherited skin diseases (Ng et al., 2009) . Already, this approach has proved insightful in revealing the molecular pathology of more than a dozen previously uncharacterized genodermatoses (for update see Cheng and Cho, 2012) . The 2012 cost of exome sequencing in a case of suspected EB is similar to that required for the skin biopsy analysis (basement membrane immunohistochemistry and transmission electron microscopy) but a key issue in terms of the clinical interface is test turnaround time. For exome sequencing, the time needed to undertake data analysis and filtering represents the major hurdle to maximizing clinical utility-sometimes deciphering the bioinformatics over a few weeks is suboptimal, at least to clinicians (and patients). Nevertheless, within the next year or so, sequencing a genome in a day will be both feasible and affordable. Combined with practical bioinformatic approaches to enable rapid targeted interrogation of a specific disease gene (or panel of genes), nextgeneration sequencing is perhaps destined to change the way that inherited skin diseases such as EB are diagnosed.
With that goal, another milestone in the diagnosis of genodermatoses will then have been reached.
INTRODUCTION
Over the past two decades, there has been tremendous progress in molecular genetics of heritable skin diseases, and as many as 500 distinct human genes are now known to harbor mutations in these diseases (Feramisco et al., 2009) . The clinical implications of this progress are evident in the diagnosis and management of these diseases. For example, (a) identification of the specific mutations can be used for confirmation of diagnosis with prognostic implications; (b) identification of mutations has facilitated assessment of the precise mode of inheritance, particularly in cases with no previous family history of the disease; and (c) identification of candidate genes and mutations has formed the basis for DNA-based prenatal testing and preimplantation genetic diagnosis in families at risk for recurrence (Uitto, 2009) . However, in spite of significant progress in identification of the molecular bases of heritable skin diseases, there has been relatively little progress until very recently in developing effective and specific treatments. This synopsis will highlight some of the milestones in progress towards treatment and cure of heritable skin diseases, primarily focusing on epidermolysis bullosa (EB) as a paradigm of such conditions, with emphasis on development of gene-, protein-, and cell-based molecular strategies just entering the clinical arena .
PRECLINICAL MODEL SYSTEMS
EB is a heterogeneous group of heritable blistering disorders due to fragility of the cutaneous basement membrane zone (Bruckner-Tuderman and Has, 2012; Fine et al., 2008; Intong and Murrell, 2012 (Siprashvili et al., 2010) . Finally, novel vertebrate model systems, such as zebrafish, have been explored as potential models for heritable skin diseases . Information gleaned from the experiments utilizing preclinical animal models has been critical for the development of gene therapy approaches for EB.
PROSPECTS OF GENE THERAPY
The first Milestone for applying gene therapy for EB took place in 2005, when cultured keratinocyte stem cells with holoclone potential were cultured from the skin of a patient with a junctional form of EB (Mavilio et al., 2006) . This patient was shown to have mutations in the LAMB3 gene, which encodes the b3-subunit polypeptide of laminin 332. The patient, a 36-year-old man, had a form of non-Herlitz junctional EB caused by compound heterozygosity for a LAMB3 null mutation and a missense mutation (E210K) that, in addition to the amino acid substitution, disrupts intron splicing. Holoclone-forming cells were not present in the blistering areas of skin, most likely because the continuous proliferative stimulus associated with the chronic wound-healing process had depleted the stem cell pool. However, biopsy from the palm area, which blisters less, if at all, allowed a sufficient number of holoclones to be cultured. The cultured cells were transduced with a Maloney leukemia virus-derived retroviral vector expressing the LAMB3 complementary DNA, and these cells were then used to prepare genetically corrected epidermal grafts in culture (Figure 1 ). The grafts were transplanted onto selected areas of the patient's legs, which were prepared for acceptance of the graft by laser ablation of the deficient epidermis. Engraftment was shown to result in synthesis and proper assembly of normal levels of functional laminin 332, which clinically resulted in development of adherent epidermis that remained stable and did not demonstrate blistering (Mavilio et al., 2006) . A published 3.5 year follow-up noted that on clinical examination, no blisters were observed in the transplanted area of skin, and the regenerated skin was stable, normal looking, and functionally resilient to mechanical trauma (De Luca et al., 2009) . There was no evidence of inflammation, and specific tests carried out 3 and 6 months after the transplantation procedure indicated the absence of both humoral and T cell-mediated cytotoxic immune responses against the transgene product. It should be noted that one of the mutant alleles contained a single point mutation (E210K), which allowed residual expression of some laminin 332. Thus, the introduction of the complementary DNA-derived laminin b3 polypeptide was not recognized as a new protein by the patient's immune system, and no evidence of rejection has been noted. Although this study clearly provided proof-of-principle of ex vivo keratinocyte therapy for EB, there have been significant concerns regarding this approach. One of them revolves around the safety of the retroviral vectors used to integrate the transgene into the genome, and specifically, the concern highlights the possibility that random insertion of the transgene results in activation of proto-oncogenes or inactivation of tumor suppressive genes (De Luca et al., 2009) . These concerns were raised in response to clinical trials in which introduction of the curative transgene into hematopoietic progenitor cells of patients with X-linked severe combined immunodeficiency caused activation of a T cell proto-oncogene, resulting in leukemia (Hacein-Bey-Abina et al., 2003) . Although it has been suggested that, on statistical grounds, the probability of such an event to occur is extremely low, and that the retroviral integration into the genome may not be random, these concerns have resulted in the conclusion that the Maloney leukemia virus long-terminal repeatbased vectors are not acceptable for genetic modification of stem cells, and such clinical trials are now banned by the regulatory agencies in many countries in Europe (see De Luca et al., 2009) . Nevertheless, there have been significant improvements in vector design, and many of them have potentially a more favorable safety profile due to targeted integration sites and self-inactivating properties (Titeux et al., 2010) . On the basis of these considerations, clinical gene therapy trials focusing on the recessive dystrophic forms of EB have been recently initiated (Dr. Alfred Lane, Stanford University, personal communication).
In the context of ex vivo keratinocyte gene therapy, the phenomenon known as revertant mosaicism is of considerable interest (Lai-Cheong et al., 2011; Pasmooij and Jonkman, 2012) . Revertant mosaicism in skin diseases was originally noted in a patient with a junctional form of EB, where areas of skin were shown to reacquire the wild-type phenotype through naturally occurring mitotic gene conversion (Jonkman et al., 1997) . Thus, revertant mosaicism reflects ''natural gene therapy,'' which could provide corrected, patient-specific cells for grafting purposes (Gostynski et al., 2009) .
RNA INTERFERENCE TECHNOLOGY
Another gene therapy approach for treatment of inherited skin diseases utilizes silencing of the mutant RNA by short-interfering RNA (siRNA; Figure 2 ). Specifically, the safety and efficacy of a siRNA targeting mutant keratin 6a (N171K) has been recently reported in a patient with pachyonychia congenita (PC). The Milestone paper by Leachman et al. (2010) describes a patient with PC, a disabling keratinization disorder affecting the skin, nails, oral mucosa, hair, and teeth. This disease is inherited in an autosomal dominant fashion and often leads to painful lesions in the feet characterized by blistering and callus formation on the soles. PC is caused by mutations in either keratin 6, 16, or 17 genes, and the mutant polypeptides cause the clinical manifestation by dominant-negative interference . The approach of this study was to elicit a selective depletion of the mutant keratin by injection of siRNA using a siRNA molecule carefully selected to be mutantspecific and not interfere with the wildtype K6a mRNA.
This double-blind study consisted of injection of the siRNA to one foot while the other foot received a vehicle-control solution (Leachman et al., 2010) . The treatment consisted of 17 weeks of two times weekly injections and was followed by a 3-month washout. Careful assessment of the clinical signs and symptoms revealed definitive improvement, and the size of the callus in siRNA-injected sites was getting smaller. Thus, this first-in-human doubleblinded phase 1b clinical trial suggested the proof-of-principle of RNA interference technology for patients with keratinization disorders.
This study also highlighted some of the drawbacks of this approach. First, the siRNA was delivered by direct injection to the lesional skin, resulting in intense pain (Leachman et al., 2010) . Consequently, significant efforts are now focusing on improved delivery methods, such as pharmaceutical formulations for topical, non-invasive delivery for PC, and other keratin disorders (Kaspar et al., 2009; McLean and Moore, 2011) . Another concern is that although there was a dramatic and specific response in the treated area of skin, the improvement appeared to be temporary, and upon discontinuation of the treatment, the lesions returned to their original size. Thus, continuous treatment by improved topical delivery system might be required for this approach (Smith et al., 2008) . Finally, it has been pointed out that one of the disadvantages of the allele-specific gene silencing approach is that the US Food and Drug Administration and corresponding international agencies may consider each mutation-specific siRNA as a separate entity requiring individual toxicity studies and regulatory approval (see Uitto et al., 2012) . Thus, an alternative approach to the mutant allele-specific ablation, for example, in case of PC, would be total silencing of all KRT6A alleles, both mutant and wild type (Figure 2 ). It should be noted that the blistering phenotype does not occur in the complete absence of K6a because of functional redundancy with K6b and K6c, allowing normal intermediate filament network integrity. Clinical trials are now being contemplated using these approaches for PC and other keratinization disorders (Dr Irwin McLean, University of Dundee, personal communication).
ALLOGENEIC FIBROBLAST THERAPY
The Milestone article by Wong et al. (2008) reported on a clinical trial in which the potential for intradermal injections of allogeneic fibroblasts were assessed in individuals with recessive dystrophic EB (RDEB). These studies were based on the premise that human skin fibroblasts, in addition to keratinocytes, express type VII collagen (Stanley et al., 1985; Chen et al., 1994) . Furthermore, previous animal studies have suggested that COL7A1 genecorrected human RDEB fibroblasts overexpressing type VII collagen, when injected intradermally into immunodeficient mouse skin or into a transplanted human RDEB skin xenograft, allowed sustained human type VII collagen deposition at the dermal epidermal junction, accompanied by anchoring fibril formation (Woodley et al., 2003) . These observations lead the authors to postulate that injection of a sufficient number of normal fibroblasts could lead to amelioration of the skin phenotype in patients with RDEB.
Five subjects were injected with cultured autologous fibroblasts into the edge of unblistered skin, and the expression of type VII collagen was evaluated by immunofluorescence in biopsies at 2 weeks and 3 months after a single injection (Wong et al., 2008) . Significant, up to B2-fold increase in type VII collagen immunostaining was noted at sites injected with parental Figure 2 . Small interfering RNA (siRNA) strategies for autosomal dominant keratin 6a disorders by targeting either mutant or both mutant and wild-type alleles. (a) In normal keratinocytes, synthesis of K6a (blue), K6b (red), and K6c (green) occurs; (b) in pachyonychia congenita keratinocytes with a heterozygous missense mutation in KRT6A, there is a dominant-negative interference between the wild-type and mutant K6a protein that perturbs the entire keratin network and compromises cell integrity, leading to skin blistering as a result of minor trauma; (c) one siRNA approach is to target the mutant KRT6A allele to leave only residual wild-type KRT6A allele expression; (d) an alternative siRNA strategy is to silence all KRT6A, both mutant and wild-type-blistering does not occur in the absence of K6a because of functional redundancy with K6b and K6c, allowing normal intermediate filament network integrity (reproduced from Uitto et al., 2012). fibroblasts or from those of unrelated donors. The increased type VII collagen at the dermal-epidermal junction was accompanied with an increase in anchoring fibrils, although these were not fully developed. Nevertheless, this and complementary studies demonstrated the potential of allogeneic fibroblast therapy for treatment of RDEB (Petrova et al., 2010; Yan and Murrell, 2010) .
One of the observations in this study was that the allogeneic cells, as determined by Y chromosome positivity in female patients injected with male fibroblasts, were not detectable 2 weeks after the initial injection, yet type VII collagen deposition continued up to 3 months (Wong et al., 2008) . Although initial observations of the injection sites did not reveal evidence of significant inflammation, subsequent studies suggested a subclinical immunological mechanism by which the allogeneic fibroblasts elicit increased type VII collagen expression in the basal keratinocytes of the recipient's skin (Nagy et al., 2011) (Figure 3 ). This conclusion was supported by the observation that increased type VII collagen deposition at the dermalepidermal junction was particularly pronounced in those patients who expressed some type VII collagen at the baseline, and who, therefore, had an enhanced capacity to increase synthesis of their own mutant type VII collagen. These studies identified heparin-binding epidermal growth factor-like growth factor as a novel putative mediator induced in the recipient cells by allogeneic fibroblast injection (Figure 3) .
Although these initial studies utilized a single injection of allogeneic fibroblasts to the skin, the increase in type VII collagen persisted for several months. This can be explained, in part, by the observation that type VII collagen, once deposited to the cutaneous basement membrane zone, has a relatively long half-life as judged from mouse studies (Kern et al., 2009) . Clinical trials utilizing multiple injections at regular intervals are now being contemplated to counteract the development of chronic wounds in patients with RDEB (Dr John McGrath, St John's Institute of Dermatology, personal communication).
BONE MARROW STEM CELL THERAPY
Cell-based therapy for EB and potentially other heritable skin diseases has recently been extended to include bone marrow-derived adult stem cells. Although these cells are known to have a critical role in skin homeostasis, it has also become clear that the plasticity of these cells enables their differentiation into cell types responsible for skin regeneration after injury (Badiavas et al., 2003; Tamai et al., 2009) . The Milestone article describing the first clinical trial of allogeneic bone marrow transplantation for EB was reported by Wagner et al. (2010) . In this study seven children with severe RDEB were enrolled to be recipients of bone marrow transplantation, using standard myeloablative approach (Wagner et al., 2010) . This study was predicated on previous animal studies, which have been conducted to evaluate the potential of bone marrow-derived stem cells to treat EB. For example, bone marrow transfer into the fetal circulation of mice that are deficient in type VII collagen resulted in deposition of type VII collagen in the skin, associated with reduction in the severity of the blistering in neonatal animals (Chino et al., 2008) . Also, hematopoietic and nonhematopoetic cell populations were infused into type VII collagen knockout mice at birth, and this treatment was shown to extend the survival of the recipient mice by several weeks or months (Tolar et al., 2009) . The EB phenotype was also rescued in a type XVII collagen knockout model by bone marrow transplantation (Fujita et al., 2010) . Although type VII collagen is synthesized both by keratinocytes and fibroblasts, type XVII collagen, a component of hemidesmosomes, is synthesized exclusively by keratinocytes. Collectively, these studies demonstrated that different bone marrow-derived stem cells, including mesenchymal stem cells, can ameliorate the clinical symptoms and increase the survival rate of EB mice, thus paving a way to clinical trials in patients with different forms of EB.
Bone marrow transplantation in the children with RDEB was noted to result in synthesis of new type VII collagen and clinical improvement that was sustained for at least 1 year after the Figure 3 . Postulated mechanism by which fibroblast therapy may ameliorate the blistering tendency in recessive dystrophic epidermolysis bullosa (RDEB). (a) In normal skin, keratinocytes synthesize type VII collagen molecules (red), which assemble into anchoring fibrils. These fibrils entrap the interstitial collagen fibers in the dermis, securing the stable association at the dermal-epidermal junction. (b) In some patients with RDEB, there are only a few rudimentary anchoring fibrils, allowing formation of blisters below the lamina densa as a result of minor trauma. (c) Allogeneic fibroblasts injected directly into dermis elicit a subclinical immune reaction that leads to synthesis of heparin-binding epidermal growth factor-like growth factor (HB-EGF), which upregulates the synthesis and assembly of patient's own mutated type VII collagen. The increase in the rudimentary anchoring fibrils, which are partially functional, stabilizes the association of epidermis to the underlying dermis and ameliorates the blistering tendency (adapted from Uitto, 2011a).
transplantation (Wagner et al., 2010; . Although these preliminary studies were promising and generated cautious optimism, it should be noted that two of the seven children died as a result of complications of the bone marrow transplant procedure, which utilized traditional chemoablative preconditioning of the recipients. A second clinical bone marrow transplantation trial has been initiated with the approach to use reduced-intensity chemotherapy before transplantation, perhaps having lesser side effects with reduced morbidity and mortality (Kiuru et al., 2010) .
In addition to bone marrow transplantation, a pilot study on two patients with severe RDEB has tested the efficacy of intradermal injection of allogeneic mesenchymal stem cells into chronic ulcerative sites in these patients (Conget et al., 2010) . Improved wound healing lasting up to 4 months was attributed to replenishment of type VII collagen, which was undetectable before the procedure. Similar studies are now being developed to examine whether intradermal or intravenous injection of bone marrow-derived mesenchymal stem cells can improve the clinical outcome. Collectively, these early observations support the usefulness of bone marrow stem cell populations in the treatment of heritable skin diseases, such as RDEB.
NOVEL THERAPEUTIC APPROACHES
A number of new technologies are currently being developed for potential treatment of EB, but these have not reached the clinical trial stage as yet. One of such approaches focuses on induced pluripotent stem cells (iPSCs), which allow patient-specific cells to be corrected for the gene defect, followed by introduction of differentiated fibroblast and/or keratinocytes to the skin (Figure 4 ). This approach would circumvent the difficulties in obtaining sufficient numbers of patient-specific cells and avoid the problem of immune rejection. Recently, patient-specific iPSCs have been generated from several human diseases to investigate the disease mechanisms, test potential drugs, and develop cell-based therapies. In the case of heritable skin diseases, patient-specific iPSCs have been generated from patients with dyskeratosis congenita as well as RDEB (Agarwal et al., 2010; Itoh et al., 2011; . Although a number of technological issues still need to be resolved before iPSC-based therapy can be moved to the clinic, there is rapid technological progress in this area, and the first report of gene correction utilizing patient-specific iPSCs has already been published in a case with gyrate atrophy (Howden et al., 2011) , providing a proof-of-concept for this technology.
Another approach to counteract the clinical manifestations of EB, which has not reached the clinical trial stage yet, is potential protein-replacement therapy. This concept is again predicated on the use of Col7a1 knockout mice as a platform, which demonstrated that infusion of a purified type VII collagen results in significantly reduced blistering and extends the lifespan of these mice (Remington et al., 2009) . Again, once the type VII collagen has been properly deposited on the cutaneous basement membrane zone, the protein remains stably assembled for several months. Clinical trials utilizing GMPpurified type VII collagen are currently contemplated for patients with severe RDEB (Dr David Woodley, University of Southern California, personal communication).
Collectively, regenerative medicine for heritable skin diseases is moving very rapidly, and with novel technological innovations the field is making progress towards treatment and cure of these, currently intractable disorders.
